Study-related adverse events. by Benjamin R. Lewis (22279166)

“…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”

Study flow chart. by Benjamin R. Lewis (22279166)

“…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

“…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”

<i>M</i>. <i>bovis</i> 0690::Tn mutant failed to elicit the recruitment of neutrophils into milk spaces. by Aga E. Gelgie (17661720)

Loss of mammary fitness and virulence by <i>M</i>. <i>bovis</i> 0690::Tn mutant. by Aga E. Gelgie (17661720)

Open data. by Larissa Brazolotto Ferreira (17671168)

“…</p><p>Results</p><p>There was a significant decrease in BMD in the lumbar spine (1.107 ± 0.109 and 1.075 ± 0.112 g/cm²; <i><i>p</i></i> < 0.001), total body (1.135 ± 0.086 and 1.119 ± 0.085 g/cm²; <i><i>p</i></i> < 0.001), and total proximal femur over the six months of EBF compared to the values obtained from the same EBF group at 15 days postpartum (mean percentage decreases in BMD of −3.4 ± 3.7% (<i><i>p</i></i> < 0.001) in lumbar spine, −2.5 ± 3.4% (<i><i>p</i></i> < 0.001) in total proximal femur, and −1.7 ± 1.9% (<i><i>p</i></i> = 0.001) in total body). …”

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

The composition and validation of the optimized formula with its predicted responses according to I Optimal Design. by Randa Mohammed Zaki (21637175)

Mapping of transposon insertions in the selected mutants of <i>M</i>. <i>bovis</i> PG45. by Aga E. Gelgie (17661720)

Cytotoxicity (as of %Control) IC₅₀ value (mean ±SD in µM) of the tested compounds vs. Positive controls Cisplatin and doxorubicin against gastrointestinal and colorectal... by MohammedBashar Al-Qazzan (22439236)

Subjects:

3D and 2D pose of the docked 4-hydroxyestrdiol diagram displaying a variety of interactions with enzyme’s active region. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Cytotoxicity (as of %Control) IC₅₀ value (mean ±SD in µM) of the tested compounds vs. positive controls Cisplatin and doxorubicin against other malignancy’ cell lines ad... by MohammedBashar Al-Qazzan (22439236)

Subjects:

The role of glyoxalase system in methylglyoxal detoxification. by MohammedBashar Al-Qazzan (22439236)

Subjects:

IC₅₀ values (mean ±SD in μM) of <i><i>in vitro</i></i> DPPH-radical scavenging properties vs. ascorbic acid and antiinflammation propensities vs. indomethacin of the tes... by MohammedBashar Al-Qazzan (22439236)

Subjects:

3D and 2D pose of the docked Shikonin diagram displaying a variety of interactions with enzyme’s active region. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Classification of inactive compounds. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Active compounds identified as glyoxalase-I inhibitors. by MohammedBashar Al-Qazzan (22439236)

Subjects: